TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01260753
Drug: Fluticasone propionate nasal spray
Normalized name: fluticasone propionate Metered Dose Nasal Spray
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate nasal spray
Study: NCT03080311
Drug: APG-1252
Normalized name: APGA
DrugBank: Aminopterin (DB08878)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple dose cohorts, 30 minute IV infusion, twice weekly for 3 weeks of a cycle with 28 days.
Study: NCT02638701
Drug: Infliximab
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Please see protocol for details.
Study: NCT01254877
Drug: ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ondansetron 0.2 mg bid, oral preparation, 16 weeks
Study: NCT01254877
Drug: placebo ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Matching placebo will be prepared using a colorless strawberry syrup, simple syrup and flat Schweppes tonic water.
Study: NCT01254877
Drug: Ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ondansetron 0.8 mg bid, oral preparation, 16 weeks duration
Study: NCT02661971
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 50 mg/m², d1
Study: NCT02661971
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin 85 mg/m², d1
Study: NCT02661971
Drug: 5-Fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU 2600 mg/m², d1
Study: NCT01746875
Drug: Aflibercept
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2.0 mg monthly x 3 doses, then as needed based on recurrence of activity on OCT. If no effect after the initial 3 doses; 2.0 mg monthly x 3 doses is repeated.
Study: NCT01746875
Drug: Verteporfin
Normalized name: Verteporfin
DrugBank: Verteporfin (DB00460)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: given if aflibercept does not have any effect. Verteporfin photodynamic therapy is given in combination with aflibercept and triamcinolone. The treatment can be repeated after 3 month.
Study: NCT01258868
Drug: Celebrex
Normalized name: Celebrex
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 mg PO BID for 7 days prior to cell administration and then on days 1 through 28 of each vaccine cycle.
Study: NCT01078545
Drug: Leuprolide acetate Depot Susp. 11.25 mg (Poland), 3.75 mg (Ukraine)
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide acetate 11.25 mg every 3 months sc or im, number of injections during the trial - 5 in Poland, Leuprolide acetate 3.75 mg every 1 month sc or im, number of injections during the trial - 12 in Ukraine.
Study: NCT00088153
Drug: Physiologic Estrogen/progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Vivelle Dot patch 100 mcg twice weekly; Provera 2.5 mg daily for the first 10 days of the month
Study: NCT00410527
Drug: Merrem
Normalized name: Merrem
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03948386
Drug: isobaric bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The anesthesiologist and CRNA or resident performing the spinal will perform spinal anesthesia according to standard operating procedures with the randomly assigned local anesthetic.
Study: NCT03948386
Drug: hyperbaric bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TThe anesthesiologist and CRNA or resident performing the spinal will perform spinal anesthesia according to standard operating procedures with the randomly assigned local anesthetic.
Study: NCT03948386
Drug: isobaric mepivacaine
DrugBank: Mepivacaine (DB00961)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The anesthesiologist and CRNA or resident performing the spinal will perform spinal anesthesia according to standard operating procedures with the randomly assigned local anesthetic.
Study: NCT03357393
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam is givenas sedation to the Control arm.
Study: NCT02960906
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: For Arms 1A and 4A:~Nivolumab alone administered IV over 60 minutes at 240 mg every 2 weeks until disease progression, unacceptable toxicity or other reasons specified in the protocol.~For Arms 1B, 2B, 3B and 4B:~Nivolumab administered IV over 60 minutes at 3 mg/kg combined with ipilimumab administered IV over 30 minutes at 1 mg/kg every 3 weeks for 4 doses followed by nivolumab administered IV over 60 minutes at 240 mg every 2 weeks until disease progression, unacceptable toxicity or other reasons specified in the protocol.~Starting from the Cycle 7 possibility to switch from nivolumab 240 mg every 2 weeks to 480 mg every 4 weeks according to the Investigator's preference.
Study: NCT02960906
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: For Arms 1B, 2B, 3B and 4B:~Ipilimumab administered IV over 30 minutes at 1 mg/kg every 3 weeks combined with Nivolumab administered IV over 60 minutes at 3 mg/kg for 4 doses until disease progression, unacceptable toxicity or other reasons specified in the protocol.
Study: NCT02960906
Drug: Pazopanib
Normalized name: Pazopanib
DrugBank: Pazopanib (DB06589)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: For Arms 2C and 3C (TKI pazopanib or sunitinib):~Pazopanib 800 mg orally QD until disease progression, unacceptable toxicity or other reasons specified in the protocol
Study: NCT02960906
Drug: Sunitinib
Normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: For Arms 2C and 3C (TKI pazopanib or sunitinib):~Sunitinib 50 mg orally QD until disease progression, unacceptable toxicity or other reasons specified in the protocol
Study: NCT02732730
Drug: Truvada
Normalized name: Truvada
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 women who accept to initiate PrEP
Study: NCT00514917
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 mg/m\^2 intravenous infusion over 1 hour every 3 weeks up to 10 cycles.
Study: NCT00514917
Drug: Leuprolide
Normalized name: Leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 22.5 mg injection subcutaneously every 12 weeks up to 18 months.
Study: NCT00514917
Drug: Bicalutamide
Normalized name: Bicalutamide
DrugBank: Bicalutamide (DB01128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg tablet orally once daily for first 4 weeks of treatment.
Study: NCT02096536
Drug: Vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: vancomycin administration based on decision of treating physician
Study: NCT01877954
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03015701
Drug: Mifepristone
Normalized name: Mifepristone
DrugBank: Mifepristone (DB00834)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: a 19 norsteroid with anti-progesterone and anti glucocorticoid activity which competitively inhibits binding of the hormone to its receptor
Study: NCT01651598
Drug: BI 144807
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: multiple dose (bid, low to high dose)
Study: NCT01895998
Drug: Albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This medication will be used as routine part of pulmonary function testing to assess for airway hyperreactivity. This is routinely done in a clinical capacity for pediatric patients with various pulmonary disease processes.
Study: NCT02273453
Drug: Oxazepam
Normalized name: Oxazepam
DrugBank: Oxazepam (DB00842)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01018368
Drug: VX-770
Normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In Period 1, subjects will receive a single oral dose of VX-770 150 mg on Day 1. In Period 2, subjects will receive a single oral dose of VX-770 150 mg on Day 6.
Study: NCT01018368
Drug: Rifampin
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In Period 2, subjects will receive a daily oral dose of rifampin 600 mg on Days 1 through 10
Study: NCT03090269
Drug: Methylphenidate Pill
Normalized name: methylphenidate Pill
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-month follow-up to study the effective dose as a treatment for cocaine dependence in toxicity and reduction in cocaine use
Study: NCT02804646
Drug: recombinant human endostatin
Normalized name: Recombinant human endostatin
DrugBank: Endostatin (DB06423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: endostar was continuous intravenous transfusion for 7 days，with the dose of 15mg/m2 for one day
Study: NCT02804646
Drug: pemetrexed plus cisplatin or carboplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: the dose of pemetrexed was 500mg/m2 on day 1 of every 21 days,plus cisplatin or carboplatin.
Study: NCT03501277
Drug: Alogliptin
Normalized name: Alogliptin
DrugBank: Alogliptin (DB06203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alogliptin tablets.
Study: NCT03501277
Drug: Pioglitazone
Normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pioglitazone tablets.
Study: NCT03501277
Drug: SYR-322-4833 BL
Normalized name: BL-1020
DrugBank: BL-1020 (DB05687)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SYR-322-4833 BL FDC tablets.
Study: NCT01708837
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion rate is titrated to maintain the target BIS values
Study: NCT00977561
Drug: figitumumab
Normalized name: Figitumumab
DrugBank: Figitumumab (DB11685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Figitumumab (20 mg/kg)
Study: NCT00977561
Drug: Cisplatin (Or Carboplatin)
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin (75 mg/m2 IV on Day 1) or Carboplatin AUC 5
Study: NCT00977561
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide (100 mg/m2 IV on Days 1, 2 and 3)
Study: NCT03826004
Drug: Clemastine
Normalized name: Clemastine
DrugBank: Clemastine (DB00283)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clemastine fumarate 2mg/2ml intramuscular injection is administrated into the gluteus maximus muscle
Study: NCT03826004
Drug: Saline Solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution 2ml intramuscular injection is administrated into the gluteus maximus muscle
Study: NCT01873833
Drug: lapatinib ditosylate
Normalized name: Lapatinib Ditosylate
DrugBank: Lapatinib (DB01259)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT06021379
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: AryoTrust (AryoGen Pharmed Trastuzumab) is given at a dosing of 6 mg/m2 after adjuvant chemotherapy completion every 3 weeks for 9 cycles.
Study: NCT00195793
Drug: fenofibrate
Normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00195793
Drug: ezetimibe
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00195793
Drug: atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04696445
Drug: Morphine & Oxycodone
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine and Oxycodone are used in daily practice as part of standard care. Morphine and Oxycodone will be acquired through the clinical pharmacy of St Antonius and administered according to the standard postoperative pain protocol.
Study: NCT01509807
Drug: IV morphine sulfate or Sponsor-approved equivalent
Normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients enrolled in this group will receive IV morphine sulfate or Sponsor-approved equivalent via a patient-controlled analgesia (PCA) pump, as needed.
Study: NCT01509807
Drug: EXPAREL
Normalized name: Exparel
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients enrolled in this group will receive 266 mg EXPAREL diluted with preservative-free 0.9% normal saline to a total volume of 30 cc and administered via wound infiltration prior to wound closure. When not contraindicated, 30 mg IV ketorolac will be given at the end of surgery. If not indicated, IV non-steroidal anti-inflammatory drug (NSAID) may be substituted per the site's standard of care.
Study: NCT02980653
Drug: Megestrol acetate (MA) 400 mg/day
DrugBank: Megestrol acetate (DB00351)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate (MA) will be given on 400 mg/day as eligible patient begin CCRT. Total treatment period is for a maximum of 12 weeks calculated from the date of first dose.
Study: NCT00069745
Drug: Satraplatin
Normalized name: Satraplatin
DrugBank: Satraplatin (DB04996)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00069745
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01449487
Drug: PPC-5650
Normalized name: GLYCERIN 2 g in 100 mL TOPICAL CREAM [Absolute PPC]
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for administration in the rectum Single dose of 25µg/ml at a volume of 50ml
Study: NCT02173951
Drug: Deferiprone
Normalized name: Deferiprone
DrugBank: Deferiprone (DB08826)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: in arm 1 ( active comparator) will receive a starting dose of Deferiprone (DFP) 50mg⁄ kg ⁄ d, administered orally 3 times daily. Routine dose adjustments will be made according to serum ferritin trends and safety.~Patients reaching serum ferritin ≥1000 will be subjected to dose escalation of DFP to 75 mg/kg/d.~Patients in Placebo Comparator arm when reaching end point elevation of SF to around 1000 ng/ml or more or Tsat \> 90 % and or LPI \> 0.6 will start deferiprone 75 mg/kg/d
Study: NCT02068599
Drug: TV-45070
Normalized name: Tv-3326 free base
DrugBank: Ladostigil (DB16213)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TV-45070 ointment administered twice a day (morning and evening) to target knee. Participants were provided with a laminated instruction sheet including pictures that both described and illustrated how the ointment was to be spread over the entire knee anteriorly, medially, and laterally in a thin layer that fully covered the area. The ointment was gently massaged into the skin.
Study: NCT02959606
Drug: Sarpogrelate SR 300mg
Normalized name: Sarpogrelate
DrugBank: Sarpogrelate (DB12163)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02959606
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00291915
Drug: Adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01106950
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as a 1 hour intravenous infusion once a day for 5 doses beginning on day -6.
Study: NCT01106950
Drug: Denileukin diftitox
Normalized name: Denileukin diftitox
DrugBank: Denileukin diftitox (DB00004)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 12 ug/kg/day will be administered on day -1 and day -2 intravenously.
Study: NCT01106950
Drug: IL-2
Normalized name: IL-2
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered after NK cell infusion, 10 million units every other day for a total of 6 doses. (Patients weighing less than 45 kilograms will receive a dose of 5 million units/m\^2 every other day for 6 doses).
Study: NCT04799873
Drug: AAT( Alpha 1 Antitrypsin)
Normalized name: ARO-AAT
DrugBank: Fazirsiran (DB17891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AAT administration based on clinical indication
Study: NCT00680173
Drug: pegylated interferon alpha 2a and plus ribavirin
Normalized name: Pegylated interferon alpha-2a
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks, follow up for 24 weeks
Study: NCT00448149
Drug: Sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A dose of 400mg of Nexavar® will be administered orally twice a day, daily, without an interruption per 4 week cycle for 2 cycles. If responding, additional therapy will be given.
Study: NCT01428128
Drug: Arsenic Trioxide
Normalized name: Arsenic Trioxide
DrugBank: Arsenic trioxide (DB01169)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: IV; 0.005mg/kg. Infusion on Days -3, -2 and -1 of Chemo Cycles 2, 4, and 6 (if more than 4 cycles received).
Study: NCT00118287
Drug: azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given SC or IV
Study: NCT03478995
Drug: GX-I7
Normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GX-I7 25mg/ml/vial
Study: NCT03402087
Drug: BMS-986165
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Specified dose on specified days
Study: NCT00762177
Drug: Fluoride
Normalized name: Fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brush twice a day for 14 days
Study: NCT00762177
Drug: Fluoride, Triclosan
DrugBank: Triclosan (DB08604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brush twice daily for 14 days
Study: NCT00762177
Drug: Stannous Fluoride
Normalized name: Stannous Fluoride
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brush twice daily for 14 days
Study: NCT03923842
Drug: Denosumab Inj 120 MG/1.7ML
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Denosumab 120 mg sc on day -15, -8 and day 1, followed by Denosumab 120 mg sc q4wks + platinum based drugs q3wks + Gemcitabine 1250 mg/sm day 1,8 q3wks for 6 cycles. Denosumab 120 mg sc q4wks will continue for 12 months since chemotherapy end.
Study: NCT00541775
Drug: Sitagliptin
Normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sitagliptin 100 mg administered as one oral tablet once daily in the morning for up to 18 weeks.
Study: NCT00541775
Drug: Comparator: Rosiglitazone
DrugBank: Rosiglitazone (DB00412)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rosiglitazone 8 mg administered as two 4 mg capsules once daily in the morning for up to 18 weeks.
Study: NCT00541775
Drug: Comparator: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Open-label metformin was supplied by the Sponsor as 500, 850, or 1000 mg oral tablets administered at a daily dose of \>= 1500 mg.
Study: NCT00032487
Drug: Insulin
Normalized name: Insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin (intermediate or long-lasting) in a.m. 1 unit 9 lbs Arm 1 Insulin (intermediate or long-lasting) in a.m. 1 unit 9 lbs, add one injection of insulin Arm 2
Study: NCT00032487
Drug: Glimepiride
Normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glimepiride 2 mg Arm 1 Glimepiride 8 mg Arm 2
Study: NCT00032487
Drug: Rosiglitazone
Normalized name: Rosiglitazone
DrugBank: Rosiglitazone (DB00412)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rosiglitazone 4 mg Arm 1 Rosiglitazone 4 mg bid Arm 2
Study: NCT00032487
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin 500 mg (go up to 1000 mg) Arm 1 Metformin 500 mg (go up to 2000 mg) Arm
Study: NCT00513630
Drug: Glipizide
Normalized name: Glipizide
DrugBank: Glipizide (DB01067)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00513630
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02478502
Drug: cabazitaxel
Normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cabazitaxel is given to patients with progressive testicular cancer after cisplatin-based chemotherapy
Study: NCT04518410
Drug: SNG001
Normalized name: SNG001
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.3 mL solution administered once daily for 14 days using Aerogen Ultra nebulizer (inhalation device). Participants are no longer being randomized to this intervention.
Study: NCT04518410
Drug: Camostat
Normalized name: camostat
DrugBank: Camostat (DB13729)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg (2 x 100 mg) film-coated tablets administered orally every 6 hours for 7 days. Participants are no longer being randomized to this intervention.
Study: NCT04518410
Drug: CASIRIVIMAB + IMDEVIMAB
Normalized name: casirivimab / imdevimab
DrugBank: Imdevimab (DB15940)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 600 mg casirivimab and 600 mg imdevimab, administered together as single IV infusion as one-time dose at study entry. Participants are no longer being randomized to this intervention.
Study: NCT04518410
Drug: Placebo for Bamlanivimab 7000mg
Normalized name: Bamlanivimab
DrugBank: Bamlanivimab (DB15718)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.
Study: NCT04518410
Drug: Placebo for Bamlanivimab 700mg
Normalized name: Bamlanivimab
DrugBank: Bamlanivimab (DB15718)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.
Study: NCT04518410
Drug: Placebo for Camostat
DrugBank: Camostat (DB13729)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg (2 x 100 mg) film-coated tablets administered orally every 6 hours for 7 days. Participants are no longer being randomized to this intervention.
Study: NCT03357393
Drug: Propofol-Lipuro
Normalized name: PROPOFOL-LIPURO
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol is given as sedation to both intervention arms.
Study: NCT04518410
Drug: Placebo for SAB-185 (low dose)
Normalized name: SAB-185
DrugBank: SAB-185 (DB16491)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.